We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02756793
Previous Study | Return to List | Next Study

Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02756793
Recruitment Status : Active, not recruiting
First Posted : April 29, 2016
Last Update Posted : August 24, 2022
Information provided by (Responsible Party):
David Palma, Lawson Health Research Institute

Brief Summary:
A multicenter randomized phase II trial of stereotactic body radiotherapy for oligo-progressive metastatic cancers. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiotherapy (SABR) to all sites of oligo-progressive lesions.Radiotherapy will be administered as soon as possible following randomization, and subjects will be followed until next disease progression. The primary outcome is progression-free survival (PFS).

Condition or disease Intervention/treatment Phase
Metastatic Cancer Radiation: Stereotactic Ablative Radiotherapy (SABR) Other: Standard of Care Treatment Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial): A Randomized Phase II Trial
Study Start Date : October 2016
Actual Primary Completion Date : July 31, 2022
Estimated Study Completion Date : June 2026

Arm Intervention/treatment
Active Comparator: Standard of Care Treatment

Patient treatment may include the following 3 options, at the discretion of the treating physicians:

  • Continue with current systemic agent(s)
  • Observation
  • Switch to next-line treatment
Other: Standard of Care Treatment

May include:

  • Continue with current systemic agent(s)
  • Observation
  • Switch to next-line treatment

Palliative radiotherapy is allowed in this arm.

Experimental: Stereotactic Ablative Radiotherapy (SABR)
SABR is delivered to all sites of progressive disease with continuation of current systemic agents. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in Arm 1.
Radiation: Stereotactic Ablative Radiotherapy (SABR)
Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.

Primary Outcome Measures :
  1. Progression-Free Survival [ Time Frame: 5 years ]
    Progression-Free Survival is defined as the time from randomization to progression of disease or death from any cause

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 5 years ]
    Overall survival is defined as they time from randomization to death from any cause

  2. Quality of Life [ Time Frame: 5 years ]
    Quality of life in domains of physical, social/family, emotional, and functional well-being will be assessed with the Functional Assessment of Cancer Therapy (FACT-G)

  3. Toxicity [ Time Frame: 5 years ]
    Toxicity related to radiation treatment will be assessed by the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4 for each organ treated (i.e. liver, lung, bone)

  4. Lesional Control Rate [ Time Frame: 5 years ]
    Local control rate of lesions treated with SABR

  5. Total Time on Chemotherapy [ Time Frame: 5 years ]
    Duration of systemic therapy treatment

  6. Duration of current systemic agent treatment after SABR [ Time Frame: 5 years ]
    Arm 2 only

  7. Location of sites of further progression after SABR [ Time Frame: 5 years ]
    Sites of progressive disease after SABR are captured in follow up

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 or older
  • Willing to provide informed consent
  • Histologically confirmed Non-Small Cell Lung Cancer (NSCLC) with metastatic disease detected on imaging. Biopsy of metastasis at some time point prior to enrollment is preferred, but not required.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Life expectancy > 3 months
  • Patient has received treatment with systemic therapy (either cytotoxic or targeted, including maintenance therapies) during the past 6 weeks. This most recent systemic therapy agent must have been delivered for a total of at least 3 months, with an initial partial response (PR), complete response (CR) or stable disease (CR) prior to the development of oligo-progressive lesions.
  • Oligoprogression, defined as Response Evaluation Criteria in Solid Tumors (RECIST)-documented progression in up to 5 individual lesions, with no previous radiation or radiofrequency ablation to those sites. Oligoprogression may be defined as:
  • Progression of an individual metastasis according to RECIST 1.1 criteria
  • Unambiguous development of a new metastatic lesion at least 5mm in size
  • Progressive enlargement of a known metastasis on 2 consecutive imaging studies 2- 3 months apart with a minimum 5mm increase in size from baseline
  • All sites of oligoprogression can be safely treated
  • Maximum 3 progressing metastases in any single organ system (i.e. lung, liver, brain, bone), and the total number of metastases must be 5 or less

Note for Patients with Brain Metastases: For patients with brain metastases and oligo-progression elsewhere where stereotactic radiation to the brain is deemed to be warranted, this must be specified prior to randomization. If randomized to Standard Arm, patient would receive stereotactic radiation to brain only. If randomized to Experimental Arm, patient would receive stereotactic radiation to brain and to body lesions

Exclusion Criteria:

  • Serious medical comorbidities precluding radiotherapy, such as ataxia-telangiectasia or scleroderma. For patients with oligoprogressive lesions in the lung or thorax, this includes interstitial lung disease
  • Prior radiotherapy to a site requiring treatment
  • Malignant pleural effusion
  • Inability to treat all sites of enlarging, oligoprogressive disease
  • Clinical or radiological evidence of spinal cord compression or tumor within 3mm of spinal cord on MRI
  • Any other condition which in the judgment of the investigator would make the patient inappropriate for entry into this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02756793

Layout table for location information
Canada, Alberta
Alberta Health Services-Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
BC Cancer - Prince George
Prince George, British Columbia, Canada, V2M 7E9
BC Cancer Fraser Valley Centre
Surrey, British Columbia, Canada, V3V 1Z2
BC Cancer Agency Branch
Vancouver, British Columbia, Canada, V5Z 4E6
BC Cancer - Victoria Centre
Victoria, British Columbia, Canada, V8R 4X1
Canada, Ontario
London Regional Cancer Program
London, Ontario, Canada, N6A 4L6
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G1X6
Sponsors and Collaborators
Lawson Health Research Institute
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: David Palma, Principal Investigator, Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT02756793    
Other Study ID Numbers: STOP
First Posted: April 29, 2016    Key Record Dates
Last Update Posted: August 24, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms, Second Primary
Neoplastic Processes
Pathologic Processes